High Growth Tech Stocks To Watch In January 2025

As global markets navigate a choppy start to the year, with small-cap stocks underperforming and inflation concerns persisting, investors are closely watching economic indicators and policy updates that could influence market sentiment. In such an environment, identifying high-growth tech stocks requires careful consideration of their potential to innovate and adapt amidst economic uncertainties.

Top 10 High Growth Tech Companies

Name	Revenue Growth	Earnings Growth	Growth Rating
eWeLLLtd	26.41%	28.82%	★★★★★★
CD Projekt	23.18%	27.00%	★★★★★★
Waystream Holding	22.09%	113.25%	★★★★★★
Pharma Mar	25.43%	56.19%	★★★★★★
AVITA Medical	33.33%	51.81%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
Alnylam Pharmaceuticals	21.47%	56.58%	★★★★★★
Elliptic Laboratories	70.09%	111.37%	★★★★★★
Travere Therapeutics	29.58%	61.86%	★★★★★★
Initiator Pharma	1.82%	0.25%	★★☆☆☆☆

Click here to see the full list of 1223 stocks from our High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Pharma Mar (BME:PHM)

Simply Wall St Growth Rating: ★★★★★★

Overview: Pharma Mar, S.A. is a biopharmaceutical company focused on the research, development, production, and commercialization of bio-active principles for oncology across several countries including Spain, Italy, Germany, Ireland, France, and the United States with a market cap of approximately €1.34 billion.

Operations: The company generates revenue primarily from its oncology segment, amounting to approximately €154.75 million.

Pharma Mar, with a projected annual revenue growth of 25.4%, outpaces the Spanish market's average of 4.8%. This robust expansion is complemented by an impressive forecast in earnings growth at 56.2% per year, significantly higher than the local market expectation of 8.2%. Despite these strong financial indicators, Pharma Mar faces challenges with a highly volatile share price and a recent dip in profit margins from 8.3% to just 0.4%. The company remains active in innovation, as evidenced by recent positive results from its Phase 3 clinical trial for Zepzelca® in combination therapy for lung cancer, positioning it well for future regulatory approvals and sustained market presence.

• Click here and access our complete health analysis report to understand the dynamics of Pharma Mar.

• Explore historical data to track Pharma Mar's performance over time in our Past section.

Rakus (TSE:3923)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Rakus Co., Ltd. is a company that, along with its subsidiaries, offers cloud services in Japan and has a market capitalization of approximately ¥319.95 billion.

Operations: Rakus generates revenue primarily from its Cloud Business, which accounts for ¥37.28 billion, while the IT Outsourcing Business contributes ¥6.49 billion.

Rakus Co., Ltd. has demonstrated a robust financial trajectory, with recent revisions indicating an upward trend in both dividends and earnings forecasts for FY 2025. The company's dividend per share has been adjusted from JPY 3.90 to JPY 4.10, reflecting confidence in its financial health amidst a significant increase in October sales to JPY 4,165 million. Furthermore, Rakus revised its annual earnings guidance upwards with expected net sales reaching JPY 48,500 million and profits attributable to owners at JPY 7,310 million. This positive adjustment is underpinned by an impressive annual revenue growth rate of 16.7% and an even more striking earnings growth forecast of 25.6% per year, significantly outpacing the Japanese market average of just over 8%.

• Navigate through the intricacies of Rakus with our comprehensive health report here.

• Gain insights into Rakus' past trends and performance with our Past report.

JMDC (TSE:4483)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: JMDC Inc. offers medical statistics data services in Japan and has a market capitalization of approximately ¥241.58 billion.

Operations: JMDC Inc. generates revenue primarily from its Healthcare-Big Data segment, accounting for ¥30.74 billion, followed by Tele-Medicine at ¥5.90 billion and Pharmacy Support contributing ¥1.25 billion. The company focuses on providing specialized data services within the medical sector in Japan.

JMDC Inc. is navigating a complex landscape with its recent decision to merge with wholly owned subsidiary cotree Co., Ltd., effective March 2025, signaling strategic consolidation in its operations. Despite a volatile share price over the past three months, the company's revenue growth at 17.7% annually outpaces the Japanese market average of 4.3%. However, challenges persist as JMDC's profit margins have dipped to 10.9% from last year’s 18.6%, reflecting tighter operational efficiencies needed amidst competitive pressures. The projected earnings growth of nearly 24.9% annually suggests potential for recovery and adaptation in an evolving industry landscape where innovation and strategic agility remain critical.

• Get an in-depth perspective on JMDC's performance by reading our health report here.

• Evaluate JMDC's historical performance by accessing our past performance report.

Seize The Opportunity

• Access the full spectrum of 1223 High Growth Tech and AI Stocks by clicking on this link.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com